89BIO INC. - COMMON STOCK

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

15 Nov 2024 07:05:00 By Nasdaq GlobeNewswire

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

12 Nov 2024 22:58:01 By Nasdaq GlobeNewswire

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

12 Nov 2024 15:01:31 By Nasdaq GlobeNewswire

89bio Reports Third Quarter 2024 Financial Results and Corporate Updates

07 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

89bio to Participate in the UBS Global Healthcare Conference

05 Nov 2024 15:05:00 By Nasdaq GlobeNewswire

89bio to Present New Analyses from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at AASLD The Liver Meeting® 2024

15 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

11 Oct 2024 15:05:00 By Nasdaq GlobeNewswire

89bio to Participate in the H.C. Wainwright 8th Annual MASH Investor Conference

30 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

19 Sep 2024 15:03:00 By Nasdaq GlobeNewswire

89bio Announces Appointment of Teresa Perney, Ph.D. as Chief Regulatory and Quality Officer

16 Sep 2024 15:05:00 By Nasdaq GlobeNewswire

89bio to Participate in Upcoming Investor Conferences

29 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

89bio Appoints Francis Sarena as Chief Operating Officer

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

89bio Reports Second Quarter 2024 Financial Results and Corporate Updates

05 Aug 2024 15:05:00 By Nasdaq GlobeNewswire

89bio Appoints Charles McWherter, Ph.D., to its Board of Directors

05 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

12 Jul 2024 15:05:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

14 Jun 2024 15:05:00 By Nasdaq GlobeNewswire

89bio to Present 48-Week Data from ENLIVEN Phase 2b Pegozafermin Trial in Metabolic Dysfunction-Associated Steatohepatitis (MASH) at EASL International Liver Congress

22 May 2024 15:05:00 By Nasdaq GlobeNewswire

89bio Initiates Phase 3 ENLIGHTEN-Cirrhosis Trial of Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Patients with Compensated Cirrhosis

14 May 2024 07:00:00 By Nasdaq GlobeNewswire

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 May 2024 15:05:00 By Nasdaq GlobeNewswire